Insulin 320

Next Previous
Drug Profile

Insulin 320

Alternative Names: I320

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 11 Sep 2017 Adverse events and pharmacodynamics data from a preclinical trial presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 01 Dec 2015 Novo Nordisk completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in Germany (NCT02479022)
  • 01 Jun 2015 Phase-I clinical trials in Type-2 diabetes mellitus (In volunteers) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top